Tesamorelin
Growth Hormone-Releasing Hormone (1-44) amide
Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog specifically indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It works by stimulating the pituitary gland to release growth hormone, leading to targeted reduction in visceral adipose tissue through enhanced lipolysis and fat metabolism.
Daily Implementation Guide
Daily Implementation Schedule
Lifestyle Integration Strategies
Nutrition Optimization
- •High-protein meals (30-40g per meal)
- •Eat slowly to enhance satiety effects
- •Stay hydrated (3+ liters daily)
- •Avoid high-fat meals on injection day
Exercise Enhancement
- •Start with 150 min moderate exercise weekly
- •Resistance training 2-3x per week
- •Monitor energy levels during escalation
- •Adjust intensity based on side effects
Sleep & Recovery
- •Maintain consistent sleep schedule
- •Monitor for sleep quality improvements
- •Track energy levels throughout day
- •Adjust injection timing if affecting sleep
Progress Tracking
SUCCESS MILESTONES
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Tesamorelin (Egrifta) is an FDA-approved prescription medication that should only be used under the supervision of a qualified healthcare provider. Treatment requires proper patient selection, monitoring, and management of potential side effects. Patients must be evaluated for contraindications including active malignancy and diabetic complications. Regular monitoring of glucose levels, IGF-1, and treatment response is essential for safe and effective use.